$2.15
7.50%
Nasdaq, Dec 26, 03:30 pm CET
ISIN
US7443752057
Symbol
PMD

Psychemedics Corporation Stock price

$2.30
-0.04 1.71% 1M
-0.15 6.12% 6M
-0.66 22.30% YTD
-0.60 20.55% 1Y
-4.81 67.65% 3Y
-7.17 75.70% 5Y
-12.50 84.46% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.15 6.98%
ISIN
US7443752057
Symbol
PMD
Sector

Key metrics

Market capitalization $13.56m
Enterprise Value $13.73m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 33.49
EV/Sales (TTM) EV/Sales 0.68
P/S ratio (TTM) P/S ratio 0.67
P/B ratio (TTM) P/B ratio 2.49
Dividend yield 9.13%
Last dividend (FY22) $0.21
Revenue growth (TTM) Revenue growth -11.16%
Revenue (TTM) Revenue $20.26m
EBIT (operating result TTM) EBIT $-2.93m
Free Cash Flow (TTM) Free Cash Flow $410.00k
Cash position $1.41m
EPS (TTM) EPS $-0.51
Short interest 0.31%
Show more

Is Psychemedics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Psychemedics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Psychemedics Corporation:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Psychemedics Corporation:

Buy
100%

Financial data from Psychemedics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
20 20
11% 11%
100%
- Direct Costs 12 12
12% 12%
62%
7.77 7.77
10% 10%
38%
- Selling and Administrative Expenses 7.60 7.60
9% 9%
38%
- Research and Development Expense 0.86 0.86
27% 27%
4%
-0.69 -0.69
253% 253%
-3%
- Depreciation and Amortization 2.24 2.24
22% 22%
11%
EBIT (Operating Income) EBIT -2.93 -2.93
22% 22%
-14%
Net Profit -3 -3
23% 23%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Psychemedics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Psychemedics Corporation Stock News

Neutral
GlobeNewsWire
27 days ago
DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq: PMD) (the “Company”), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common ...
Neutral
GlobeNewsWire
about 2 months ago
DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024.
Neutral
GlobeNewsWire
3 months ago
DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report.
More Psychemedics Corporation News

Company Profile

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.

Head office United States
CEO Brian Hullinger
Employees 116
Founded 1986
Website www.psychemedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today